A Forecast Insight Report Into The Antidiabetics Market - Switching To New Molecule Antidiabetics Drives Market Growth

Main Category: Diabetes
Also Included In: Pharma Industry / Biotech Industry
Article Date: 10 Oct 2008 - 5:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Research and Markets has announced the addition of the "Forecast Insight: Antidiabetics - Switching to New Molecule Antidiabetics Drives Market Growth" report to their offering.

The antidiabetics market is expected to reach $29 billion, across the seven major markets, by 2017. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists, and large growth in patient numbers. However, patent expiries of the glitazone (TZDs) class will restrain market growth.

Scope

- Description of the competitive landscape in antidiabetics across seven major markets with market definition and overview.

- Event-driven updated sales forecasts for 2008-17 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan.

- Analysis of major events and brand dynamics affecting the diabetes market.

Highlights of this title

The antidiabetics market in the seven major markets is expected to grow from $18 billion in 2007 to $29 billion in 2017 at a rate of 5% CAGR. Significant unmet needs remain in diabetes fueling a large pipeline. The epidemiological growth of the market, driven by the obesity epidemic and improved diagnosis rates, is further driving the market.

The glitazone class was the major non-insulin antidiabetic therapy in 2007 driven by the Actos and Avandia franchises. Both of these drugs will lose their marketing leading positions following patent expiry in 2011 and 2013. Safety concerns over Avandia remain unresolved and the drug will continue to continue to lose market share.

The incretin mimetics are likely to be the beneficiaries of Avandias problems and the DPP-IV inhibitors are expected to become the leading non-insulin antidiabetics. GLP-1 agonists are also expected to record significant sales. The two classes will provide over 75% of the sales from newly launched antidiabetics.

Key reasons to purchase this title

- Quantify the future size of the antidiabetics market and identify opportunities for new products.

- Learn how product expiries will shape the antidiabetics market.

- Understand the barriers to uptake for novel antidiabetic agents, and the implications of recent regulatory reviews.

Key Topics Covered:

- Market Definition and Overview
- Brand Dynamics
- Overview of competitive landscape
- Franchise overview
- Sales forecasts
- List of Tables
- List of Figures

For more information visit here.

Research and Markets